Mineralys Therapeutics, Inc. financial data

Symbol
MLYS on Nasdaq
Location
Radnor, PA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2630% % 116%
Return On Equity -33% % 52%
Return On Assets -32% % 49%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 82,399,478 shares 26%
Common Stock, Shares, Outstanding 81,536,557 shares 64%
Entity Public Float $676,000,000 USD 69%
Common Stock, Value, Issued $8,000 USD 60%
Weighted Average Number of Shares Outstanding, Basic 67,656,355 shares 39%
Weighted Average Number of Shares Outstanding, Diluted 67,656,355 shares 39%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $132,009,000 USD -22%
General and Administrative Expense $38,595,000 USD 62%
Operating Income (Loss) $170,604,000 USD 11%
Nonoperating Income (Expense) $15,953,000 USD 9.3%
Net Income (Loss) Attributable to Parent $154,651,000 USD 13%
Earnings Per Share, Basic -2.29 USD/shares 37%
Earnings Per Share, Diluted -2.29 USD/shares 37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $172,921,000 USD 52%
Assets, Current $661,386,000 USD 222%
Property, Plant and Equipment, Net $38,000 USD -28%
Other Assets, Noncurrent $382,000 USD -23%
Assets $661,806,000 USD 221%
Accounts Payable, Current $2,017,000 USD 321%
Accrued Liabilities, Current $13,096,000 USD -7.6%
Liabilities, Current $15,113,000 USD 3.2%
Retained Earnings (Accumulated Deficit) $457,169,000 USD -51%
Stockholders' Equity Attributable to Parent $646,693,000 USD 238%
Liabilities and Equity $661,806,000 USD 221%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $45,487,000 USD -138%
Net Cash Provided by (Used in) Financing Activities $189,279,000 USD 63%
Net Cash Provided by (Used in) Investing Activities $92,876,000 USD -66%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 81,536,557 shares 64%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $50,916,000 USD 24%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $172,921,000 USD 52%
Deferred Tax Assets, Valuation Allowance $121,248,000 USD 52%
Deferred Tax Assets, Gross $121,248,000 USD 52%
Deferred Tax Assets, Operating Loss Carryforwards $55,102,000 USD 254%
Unrecognized Tax Benefits $6,488,000 USD 44%
Additional Paid in Capital $1,103,854,000 USD 124%
Depreciation, Depletion and Amortization $15,000 USD 88%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $19,324,000 USD 70%